Cardiovascular and renal outcomes with combination exenatide and open-label SGLT2 inhibitor treatment in EXSCELL. E. Clegg,R. C. Penland, S. Bachina,D. W. Boulton,M. Thuresson,H. J. L. Heerspink, S. Gustavson,C. D. Sjostrom,J. Ruggles,A. F. Hernandez,J. B. Buse,R. J. Mentz,R. R. HolmanDIABETOLOGIA(2019)引用 0|浏览19暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要